Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.18−0.15 (-11.28%)
Close on Nov 13, 2026Market cap $118.40MP/E –Yield –
Cellectis ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -$13.01M. The highest annual figure on record is -$13.01M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.01M | – |
| FY2024 | Dec 31, 2024 | -$39.71M | – |
| FY2023 | Dec 31, 2023 | -$78.78M | – |
| FY2022 | Dec 31, 2022 | -$71.23M | – |
| FY2021 | Dec 31, 2021 | -$89.33M | – |
| FY2020 | Dec 31, 2020 | -$34.48M | – |
| FY2019 | Dec 31, 2019 | -$116.68M | – |
| FY2018 | Dec 31, 2018 | -$102.71M | – |
| FY2017 | Dec 31, 2017 | -$89.28M | – |
| FY2016 | Dec 31, 2016 | -$65.09M | – |
| FY2015 | Dec 31, 2015 | -$29.05M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | -$22.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$34.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$30.88M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.44M | – |
See a number that looks wrong?